Company profile
Ticker
SHPH
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Subsidiaries
Shuttle Pharmaceuticals, Inc. • Shuttle Diagnostics, Inc. ...
SHPH stock data
Latest filings (excl ownership)
S-1
IPO registration
5 Apr 24
8-K
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update
22 Mar 24
424B3
Prospectus supplement
22 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Shuttle Pharmaceuticals to Present at About Shuttle Pharmaceuticals
5 Mar 24
8-K
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
13 Feb 24
8-K
Entry into a Material Definitive Agreement
5 Feb 24
8-K
Shuttle Pharmaceuticals Receives FDA approval to Proceed with Phase II Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
8 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
19 Dec 23
8-K
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma
11 Dec 23
Latest ownership filings
4
Chris Senanayake
14 Mar 24
4
Hoek Michael Vander
8 Mar 24
4
Milton Brown
2 Jan 24
4
Bette Jacobs
20 Dec 23
SC 13G/A
AFH Holding & Advisory, LLC
18 Oct 23
4
Anatoly Dritschilo
18 Aug 23
SC 13G
AFH Holding & Advisory, LLC
30 May 23
SC 13G
AFH Holding & Advisory, LLC
6 Mar 23
4
Milton Brown
17 Feb 23
4
Steven M Richards
9 Jan 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.89 mm | 3.89 mm | 3.89 mm | 3.89 mm | 3.89 mm | 3.89 mm |
Cash burn (monthly) | 520.26 k | 377.60 k | 591.75 k | 461.38 k | (no burn) | 109.29 k |
Cash used (since last report) | 3.45 mm | 2.50 mm | 3.92 mm | 3.06 mm | n/a | 724.44 k |
Cash remaining | 437.31 k | 1.38 mm | -36.56 k | 827.63 k | n/a | 3.16 mm |
Runway (months of cash) | 0.8 | 3.7 | -0.1 | 1.8 | n/a | 28.9 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Mar 24 | Hoek Michael Vander | COMMON STOCK | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 103,852 |
13 Dec 23 | Bette Jacobs | Common Stock | Sell | Dispose S | No | No | 0.4632 | 4,157 | 1.93 k | 27,064 |
13 Dec 23 | Milton Brown | Common Stock | Sell | Dispose S | No | No | 0.4632 | 2,921 | 1.35 k | 1,094,610 |
14 Aug 23 | Anatoly Dritschilo | COMMON STOCK | Gift | Acquire G | Yes | No | 0 | 2,100,000 | 0.00 | 2,100,000 |
14 Aug 23 | Anatoly Dritschilo | COMMON STOCK | Gift | Dispose G | Yes | No | 0 | 2,100,000 | 0.00 | 1,104,407 |
15 Feb 23 | Milton Brown | Stock Options Class A Common Stock | Grant | Acquire A | No | No | 1.92 | 25,000 | 48.00 k | 25,000 |
News
Why Macatawa Bank Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
16 Apr 24
12 Health Care Stocks Moving In Friday's After-Market Session
22 Mar 24
Shuttle Pharmaceuticals Q4 EPS $(0.11) Down From $(0.06) YoY
22 Mar 24
Shuttle Pharmaceuticals Has Been Granted European Patent Number EP3737376 Titled "Selective Histone Deacetylase Inhibitors For The Treatment Of Human Diseases (Including Cancers, Neurological Disorders, And Immunological Disorders)"
18 Mar 24
12 Health Care Stocks Moving In Thursday's After-Market Session
25 Jan 24
Press releases
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024
3 Apr 24
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
2 Apr 24
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update
22 Mar 24
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering
13 Feb 24
Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
23 Jan 24